Diflucan Articles
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
Zeneca Pipeline Part II: Exploratory Targets
8 January 1996
Diflucan One Launched In UK
20 November 1995
Pfizer Presents Fertile Pipeline
6 November 1995
US 3rd Qrt Results: Strong Gains For Pfizer, Lilly
23 October 1995
Asilfa Of Chile Calls For IP Law Revision
31 July 1995
PhRMA Calls For Patent Term Change Withdrawal
26 June 1995
UK POM-To-P Switches At End-June
19 June 1995
Fast Growth Forecast For Antifungal market
22 May 1995
Disease ManagementThe Way Forward
15 May 1995
Pfizer Consumer Health Care
8 May 1995
TLC Launches Abelcet In 1st Market, The UK
24 April 1995
Four More POM-To-P Switches In UK
30 January 1995
Pfizer's Diflucan Efficacy In Candidemia
21 November 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
Diflucan Indication Extension
18 July 1994
CURRENCIES STILL A FACTOR IN US 1st QTR
2 May 1994
PFIZER'S "CONTINUING SUCCESS"
11 April 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
US BIOSCIENCE'S AIDS-RELATED DRUG APPROVED
10 January 1994
SINGAPORE CHARITY BUYS AIDS DRUGS
20 September 1993
SUSTAINABLE EARNINGS GROWTH FOR SANDOZ
16 August 1993
ADVANCES BY US DRUG COMPANIES IN 2nd QTR
26 July 1993
GROWING PROBLEM OF ANTIFUNGAL RESISTANCE
26 July 1993
CHILEAN COS IN FLUCONAZOLE APPEAL
14 June 1993
MURPHY'S LAW PERVADES US DRUG STOCKS
17 May 1993
PFIZER "CONFIDENT" IN CHANGING ENVIRONMENT
3 May 1993
DRUG FIRMS TO WORK TOGETHER ON AIDS R&D
26 April 1993
BROAD SPECTRUM WAY FORWARD IN ANTIFUNGALS
12 April 1993
PFIZER CONSIDERS PRICE CUTS
29 March 1993
PFIZER'S PROFITS DOWN IN JAPAN
22 March 1993
PFIZER "COMMITTED" TO HEALTH CARE AND R&D
8 March 1993
ISRAEL CONSIDERS KORATH INCLUSIONS
4 January 1993
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
DERMATOLOGISTS HIGHLIGHT SPORANOX
29 June 1992
PFIZER'S DIFLUCAN LAUNCHED IN NIGERIA
25 May 1992
JAPAN SUBSIDS DO WELL FOR MNCs
18 May 1992
PFIZER'S DIFLUCAN
6 April 1992
PFIZER'S DIFLUCAN
6 April 1992
DANISH COMPLAIN OVER GLAXO PRICING
23 March 1992
PFIZER'S DIFLUCAN & AIDS-ASSOCIATED CM
13 January 1992
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
